Biomarkers in the detection of minimal systemic dissemination in lung cancer patients
Authors:
A. Benedíková 1; J. Srovnal 1; M. Szkorupa 2; P. Skalický 2; J. Chudáček 2; T. Bohanes 2; J. Škarda 3; Z. Kolář 3; M. Hajdúch 1; J. Klein 4
Authors‘ workplace:
Laboratoř experimentální medicíny, Ústav molekulární a translační medicíny LF UP Olomouc, ředitel: Doc. MUDr. Marián Hajdúch, PhD.
1; I. chirurgická klinika LF UP a FN Olomouc, přednosta: doc. MUDr. Čestmír Neoral, CSc.
2; Ústav klinické a molekulární patologie LF UP a FN Olomouc, přednosta: Prof. MUDr. Zdeněk Kolář, CSc.
3; Chirurgické oddělení KNTB, a. s., primář: Prof. MUDr. Jiří Klein, PhD, FETCS
4
Published in:
Rozhl. Chir., 2012, roč. 91, č. 4, s. 209-215.
Category:
Original articles
Overview
Introduction:
Minimal systemic disease (MSD) means the presence of circulating or disseminated tumour cells in mesenchymal compartments of a patient´s body (lymphatic nodes, blood or bone marrow). The aim of our pilot study was to identify sensitive and specific markers for MSD detection in 50 lung cancer patients, who underwent curative surgery in the I. Department of Surgery, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital Olomouc in 2009 and 2010.
Material and methods:
Absolute gene expression of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR1), lung-specific X protein (LUNX) and hepatocyte growth factor receptor (c-met) was determined in peripheral blood, bone marrow and pulmonary blood of 50 lung cancer patients using real-time reverse transcriptase-polymerase chain reaction (real-time RT-PCR).
Results:
- The LUNX marker is specific and sensitive for MSD detection in lung cancer patients.
- The CEA positivity for MSD in the bone marrow correlated significantly with histopathological grading (GI-GIII).
- Higher expression of CEA and c-met was found in pulmonary blood of patients with hilar or mediastinal lymphadenopathy.
- Higher expression of MSD markers (CEA in bone marrow, c-met in peripheral blood and LUNX in pulmonary blood) correlated with higher pTNM classification.
Conclusion:
Minimal systemic disease detection in lung cancer patients is technically feasible using sufficiently sensitive and specific markers for RT-PCR. Minimal systemic disease detection can be used to guide further systemic treatment. This theory must be validated in a larger group of patients and correlated with clinical data, especially with survival data.
Key words:
lung cancer – minimal systemic disease – circulating tumour cells – dissemination
Sources
1. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, et al. French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer. J Clin Oncol 2002;20:47–53.
2. Pantel K, Von Knebel Doeberitz M. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol 2000;12:95–101.
3. Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase polymerase chain reaction. Cancer Res 1995; 55:3417–3420.
4. Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of diseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006;94,672–680.
5. Duda M, Vysloužil K, Skalický P, et al. Minimální reziduální choroba u kolorektálního karcinomu – nový prognostický marker v onkochirurgii. Slovenská chirurgie 2006:16–22.
6. Wong IHN, Yeo W, Cachn, AT, et al. Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for CK19 mRNA in peripheral blood of colorectal cancer patients with Dukeęs stage, serum CEA level and tumor progression. Cancer Lett 2001;162:65–73.
7. Lin Y, Chen S, Hsueh S, et al. Lack of correlation betweeen expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci 2003;1:99–102.
8. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assai. J Mol Endocrinology 2000;25:169–193.
9. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinology 2002;29:23–39.
10. Hagenbeek A. Minimal residual disease in leukemia: state of the art. Leukemia 1992;6:12–16.
11. Černý J, et al. Význam minimální reziduální nemoci a metody jejího stanovení u pacientů s některými hematologickými malignitami. Klin Onkol 2003;16:41–48.
12. Mocellin S, et al. Circulating tumor cells: the leukemic phase of solid cancers. Trends in Mol Med 2006,12:130–139.
13. Rosenberg R, Nekarda H, Thorban S, et al. Minimal residual disease in gastrointestinal tumors: tumor cell detection in bone marrow, blood and lymph nodes. Acta Med Austriaca 2002;29:42–53.
14. Srovnal J. Minimální reziduální choroba u solidních nádorů. Disertační práce. UP Olomouc 2009.
15. Uen Y, Lu CH, Tsai H, et al. Persistant presence of postoperative circulating tumor cell is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncology 2008;8:2120–2128.
16. Thomasson M, Hedman H, Guo D, et al. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT -PCR and immunohistochemical analysis. Br J Cancer 2003; 89:1285–1289.
17. Iwao K, Watanabe T, Fujiwara Y, et al. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001;91:433–437.
18. Wallace MB, Block MI, Gillanders W, et al. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest 2005;127:430–437.
19. Cheng M, Chen Y, Yu X, et al. Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer 2008;8:156–167.
20. Lv M, Wu M-Z, Zhao Y-J, et al. Expression and clinical significance of lung-specific X protein mRNA in bronchial brushing specimens from patients with or without lung cancer. Respirology 2011;16:1076–1080.
21. Sheu Ch-Ch, Chang M-Y, Chang H-Ch et al. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: A highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology 2006;70:203–211.
22. Cheng T-L, Chang M-Y, Huang S-Y, et al. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 2005;128:1453–1460.
23. Yamashita J-I, Matsuo A, Kurusu Y, et al. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: A prospective study. J Thorac Cardiovasc Surg 2002;124:299–305.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2012 Issue 4
Most read in this issue
- GIST: Current knowledge and treatment modalities
- Laparoscopic adrenalectomy – indications and selection criteria
- Prevention of parastomal hernia using laparoscopic introduction of a prosthetic mesh – initial experience
- Extragastrointestinal stromal tumor (EGIST)